The @entity2790 Treatment Study: a randomized trial determines that XXXX medication delays or prevents the onset of primary open-angle glaucoma.

@entity1 @entity725 @entity227 @entity16 @entity1939 @entity2790 @entity551
BACKGROUND: @entity725 ( @entity725 ) is one of the leading causes of @entity1939 in the United States and worldwide. Three to 6 million @entity1 in the United States are at increased risk for developing @entity725 because of @entity2790 (IOP), or @entity2790 . There is no consensus on the efficacy of medical treatment in delaying or preventing the onset of @entity725 in individuals with elevated IOP. Therefore, we designed a randomized clinical trial, the @entity2790 Treatment Study. OBJECTIVE: To determine the safety and efficacy of @entity551 medication in delaying or preventing the onset of @entity725 . METHODS: A total of 1636 @entity1 with no evidence of @entity16 , aged 40 to 80 years, and with an IOP between 24 mm Hg and 32 mm Hg in one eye and between 21 mm Hg and 32 mm Hg in the other eye were randomized to either observation or treatment with commercially available @entity551 medication. The goal in the medication group was to reduce the IOP by 20% or more and to reach an IOP of 24 mm Hg or less. MAIN OUTCOME MEASURES: The primary outcome was the development of reproducible @entity227 or reproducible optic disc deterioration attributed to @entity725 . Abnormalities were determined by masked certified readers at the reading centers, and attribution to @entity725 was decided by the masked Endpoint Committee. RESULTS: During the course of the study, the mean +/- SD reduction in IOP in the medication group was 22.5% +/- 9.9%. The IOP declined by 4.0% +/- 11.6% in the observation group. At 60 months, the cumulative probability of developing @entity725 was 4.4% in the medication group and 9.5% in the observation group (hazard ratio, 0.40; 95% confidence interval, 0.27-0.59; P<.0001). There was little evidence of increased systemic or ocular risk associated with @entity551 medication. CONCLUSIONS: @entity551 medication was effective in delaying or preventing the onset of @entity725 in individuals with elevated IOP. Although this does not imply that all @entity1 with borderline or elevated IOP should receive medication, clinicians should consider initiating treatment for individuals with @entity2790 who are at moderate or high risk for developing @entity725 .
